Response to Alemtuzumab for Leukemic Cutaneous T-Cell LymphomaResponse to Alemtuzumab for Leukemic Cutaneous T-Cell Lymphoma

Patients with leukemic cutaneous T-cell lymphoma (CTCL) who have diffuse erythema are more likely to experience complete response to alemtuzumab therapy, according to results from a small series. Reuters Health Information
Source: Medscape Dermatology Headlines - Category: Dermatology Tags: Hematology-Oncology News Source Type: news

Related Links:

ConclusionThe reason for the association between high serum copper and adverse prognosis is unknown. We hypothesize that IL-6 is secreted primarily by non-neoplastic cells at MF skin sites, leading to release of copper by the liver. Local production of IL-6 at lesion sites conceivably might also promote neoplastic cell progression via stimulation of the STAT3 pathway. Further studies on the relationship between activated tumor-associated macrophages, serum copper, IL-6 or C-reactive protein and prognosis might be informative.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Abstract Advanced-stage cutaneous T-cell lymphoma (CTCL) is usually a fatal malignancy despite optimal use of currently available treatments. In this preclinical study of novel CTCL therapy, we performed in vitro and ex vivo experiments to determine the efficacy of combination treatment with a panel of BET bromodomain inhibitors (BETi) (JQ1, OTX015, CPI-0610, I-BET762) and HDAC inhibitors (HDACi) (SAHA/Vorinostat, Romidepsin). BETi/HDACi combinations were synergistic (combination index
Source: Neoplasia - Category: Cancer & Oncology Authors: Tags: Neoplasia Source Type: research
In this study, we aimed to assess the value of iPET and ePET in the prediction of progression-free survival (PFS) and overall survival (OS) in patients with mature T-cell and NK-cell lymphomas.Methods: Data of 99 patients with mature T/NK-cell lymphomas who underwent iPET (after 2-4 cycles of chemotherapy; performed just before the next cycle) or ePET at the Kameda Medical Center were retrospectively analyzed. PET-CT scans were scored as positive or negative based on the Deauville score using a 5-point scale. While a Deauville score of 1-3 was considered to indicate complete metabolic response (CMR) (negative), a score of ...
Source: Blood - Category: Hematology Authors: Tags: 624. Hodgkin Lymphoma and T/NK Cell Lymphoma-Clinical Studies: Poster II Source Type: research
Conclusions: In pts with R/R NHL, active doses of Cami-T with acceptable safety profiles were identified for both B-cell and T-cell lymphoma during dose escalation of this study. Five out of the 10 pts on study with T-cell lymphoma treated in the 60, 80, or 100 µg/kg cohorts responded. Subtype-specific cohorts in the dose escalation portion of this study are underway to better define the recommended dose for expansion.Study sponsored by ADC Therapeutics. http://clinicaltrials.gov/show/NCT02432235.DisclosuresCollins: MSD: Consultancy, Honoraria; ADC Therapeutics: Consultancy, Honoraria, Research Funding; Roche: Consul...
Source: Blood - Category: Hematology Authors: Tags: 624. Hodgkin Lymphoma and T/NK Cell Lymphoma-Clinical Studies: Poster I Source Type: research
CONCLUSIONS: This is the first study evaluating the safety and efficacy of the BET inhibitor molibresib in NHL subjects. Overall, thrombocytopenia and other AEs were monitorable, manageable and reversible. The RP2D was identified as 60 mg QD. Single-agent activity was observed across multiple NHL subtypes at both 60 mg and 80 mg doses; most notable was a 50% response rate in subjects with CTCL. Because of the promising data, Part 2 of the BET116183 study is currently open and enrolling subjects with CTCL to better define the clinical activity of BET bromodomain inhibition in this histology.DisclosuresDickinson: GSK: Consul...
Source: Blood - Category: Hematology Authors: Tags: 626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)-Results from Prospective Clinical Trials: Poster I Source Type: research
Conclusion. Due to the good toxicity profile and the oral administration, combined therapy with momelotinib and citarinostat may represent a promising novel therapeutic modality for hematological malignancies. The study is ongoing and further investigation is required.DisclosuresNo relevant conflicts of interest to declare.
Source: Blood - Category: Hematology Authors: Tags: 802. Chemical Biology and Experimental Therapeutics: Poster II Source Type: research
Conclusions: We report a series of MTX-associated T/NK-LPD, mostly in patients with RA. MTX withdrawal maybe a reasonable first-line treatment option in MTX-associated T/NK-LPD in both the EBV+, and EBV- cases.DisclosuresPorcu: Innate Pharma: Consultancy.
Source: Blood - Category: Hematology Authors: Tags: 624. Hodgkin Lymphoma and T/NK Cell Lymphoma-Clinical Studies Source Type: research
Cutaneous T-cell lymphomas (CTCL) represent up to 80% of extranodal non-Hodgkin Lymphomas, the most common being Mycosis Fungoides (MF) with or without its leukemic stage Sezary Syndrome and Primary cutaneous CD30+ T-cell lymphoproliferative disorders. Prognosis for advanced stages is poor, with 5-year survival 40-70% for patients with advanced skin stages, and 15-40% for those with extracutaneous involvement and CD30+ transformed CTCL. The disease is considered incurable, and most patients will undergo at least two different lines of therapy, and up to 36% undergo at least four different lines due to a short duration of r...
Source: Blood - Category: Hematology Authors: Tags: 624. Hodgkin Lymphoma and T/NK Cell Lymphoma-Clinical Studies Source Type: research
Acetylation is a reversible process under the control of histone acetyltransferases (HATs) and histone deacetylases (HDACs). Acetyl proteome analysis revealed that acetylation regulates various cellular processes through both histone and non-histone proteins (Choudhary et al., Science, 2008). Subsets of diffuse large B cell lymphoma (DLBCL) and follicular lymphoma (FL) have inactivating mutations of HATs, CBP and p300 (Pasqualucci et al., Nature, 2011). In addition, p300 mutation is a poor prognostic factor in FL patients (Pastore et al., Lancet Oncol, 2015). In a mouse model, CBP deficiency promotes B cell lymphomagenesis...
Source: Blood - Category: Hematology Authors: Tags: 622. Lymphoma Biology-Non-Genetic Studies: Poster I Source Type: research
Background: Sézary syndrome (SS) is a highly-morbid T cell leukemic lymphoma with no widely-effective treatments and few preclinical models. We demonstrated effective T cell lymphoma therapy with allogeneic gene-edited anti-CD7 CARTs (Cooper et al, Leukemia, 2018). However, SS T cells typically lose CD7 but maintain ubiquitous high CD2 expression. Thus, we generated CD2- and TRAC-deleted anti-CD2 universal CARTs (UCART2) and multiple SS xenograft models (PDXs) as preclinical UCART2 testing platforms. We further tested a stable homodimeric interleukin-7 molecule, the long-acting form of recombinant human interleukin-...
Source: Blood - Category: Hematology Authors: Tags: 625. Lymphoma: Pre-Clinical-Chemotherapy and Biologic Agents: Immunologic approaches Source Type: research
More News: Cancer & Oncology | Cutaneous T cell lymphoma | Dermatology | Health | Hematology | Leukemia | Lymphoma | Skin | T-cell Lymphoma